Search the Newsreel

Trading Systems Reacting to (STOK) Volatility

The article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), noting a near-term neutral sentiment amidst mid and long-term strength, with an exceptional 61.2:1 risk-reward setup. It details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and provides multi-timeframe …

Otoki H1 Profit Rises, Revenue Up 4%

(RTTNews) - Otoki Corporation (007310.KS) on Friday reported higher revenue and profit for the first half of 2026, with operating income also increasing from the year-earlier period. Consolidated revenue rose 4.2% to KRW 1.90 trillion from KRW 1.82 trillion a year earlier. Operating income …

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares jumped over 60% after its CEO indicated the FDA is open to reviewing an updated Duchenne muscular dystrophy cell therapy submission. Separately, Cytokinetics is suing Bristol Myers Squibb to protect patents for its heart drug Myqorzo, accusing BMS of attempting to …

Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients

Wellington Management Group LLP and related entities have disclosed a 5.12% beneficial ownership stake in Cytokinetics, Incorporated (CYTK) for their clients, as detailed in an Amendment No. 2 to a Schedule 13G filing. This holding, totaling 7,116,724 shares, is managed by various Wellington investment …

CYTK Maintained by Barclays -- Price Target Raised to $110

Barclays has maintained an Overweight rating for Cytokinetics (CYTK) and increased its price target to $110, reflecting a positive outlook despite the company being unprofitable. The stock is considered undervalued by 60.9% according to GF Value™, but its GF Score™ of 51/100 indicates average …

Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb

Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment that it does not infringe on U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company also seeks an injunction to prevent infringement litigation related to its …

Form 8K Cytokinetics Inc For: 13 August By Investing.com

This article from Investing.com reports that Cytokinetics Inc. filed a Form 8K on August 13th. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of …

Rentokil Initial slides Thursday, underperforms market

Rentokil Initial PLC (RTO) shares fell 1.45% to £3.51 on Thursday, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed 30.69% below its 52-week high, which was recorded on April 15th. This performance occurred during an overall dismal …

Rentokil Initial revamps global structure to boost growth and customer focus

Rentokil Initial PLC has reorganized its global operations into two key divisions: North America and a consolidated international unit. This restructuring aims to improve customer focus and operational efficiency. The company has also appointed Matt Jochim as group chief transformation officer to lead these …

Barclays raises Cytokinetics stock price target on strong Myqorzo sales

Barclays has increased its price target for Cytokinetics (NASDAQ: CYTK) shares to $110 from $95, maintaining an Overweight rating. This upgrade follows strong second-quarter Myqorzo sales of $25.3 million, significantly beating consensus estimates. The drug's successful launch and prescription growth, alongside the company's better-than-expected …

Rentokil Initial plc (RTO) formalises two divisions and names new senior leaders

Rentokil Initial plc has restructured its operations into two formal divisions: North America and International, aiming to enhance customer focus, operational excellence, and business simplification. The company announced key leadership appointments, including Phill Wood as CEO of the International Division and Matt Jochim as …

Rentokil Initial restructures into two divisions, names leaders

Rentokil Initial plc has announced a major restructuring, dividing its operations into two distinct divisions: North America and International. This reorganization includes the appointment of Phill Wood as CEO of the International Division and Rafael Carrasco as CEO of North America. Additionally, Matt Jochim …

Tokio Marine (TSE:8766) Stock Sees Profit Reset As Margin Pressure Persists

REG - Rentokil Initial PLC - Organisational Changes & Leadership Appointments

Rentokil Initial plc announced a formalization of its operating structure into two divisions: North America and International, to enhance customer focus, operational excellence, and business simplification. The company appointed Phill Wood as CEO of the International Division and Matt Jochim as Group Chief Transformation …

Tolu Minerals (ASX:TOK): Tolukuma Drilling and Mine Restart Put PNG Gold Project in Focus

RENTOKIL INITIAL To Go Ex-Dividend On August 13th, 2026 With 0.0448 USD Dividend Per Share

RENTOKIL INITIAL is scheduled to go ex-dividend on August 13th, 2026. The company will be distributing a dividend of 0.0448 USD per share to its shareholders. Investors wishing to receive this dividend must own shares before the ex-dividend date.

Stoke Therapeutics (STOK): TD Bank, TD Securities disclose 4.9% equity stake

TD Bank and TD Securities Inc. have jointly reported a beneficial ownership of 4.9% of Stoke Therapeutics, Inc. (STOK) common stock, totaling 3,183,258 shares. The filing, a SCHEDULE 13G/A, indicates that TD Bank holds sole voting and dispositive power over 3,173,258 shares, while TD …

Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK

Handelsbanken Fonder AB increased its stake in Cytokinetics, Incorporated by 63.8% in the second quarter, now owning 405,000 shares worth $34.5 million. This comes as other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts have largely maintained a "Moderate Buy" …

Tolu Minerals Limited (ASX:TOK) Share Price Falls as Investors Monitor Tolukuma Gold Project Progress

Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cytokinetics Inc (CYTK), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 22 analysts, the stock has a strong buy recommendation with an average target price of $79.00 and an upside space …

Royal Bank of Canada Has $6.21 Million Stock Position in Rentokil Initial PLC $RTO

Royal Bank of Canada significantly increased its stake in Rentokil Initial PLC, now holding 197,383 shares valued at $6.21 million. Despite this institutional interest, RTO shares are trading near their 52-week low, indicating recent weakness. Analysts maintain a "Moderate Buy" consensus rating with an …

Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK

Dimensional Fund Advisors LP significantly increased its stake in Cytokinetics, Incorporated, acquiring an additional 75.2% of shares, totaling 94,503 shares valued at $6.23 million. Other institutional investors also raised their positions, reflecting broadly positive sentiment despite recent insider selling and a year-over-year revenue decline. …

Dimensional Fund Advisors LP Trims Stock Holdings in Rentokil Initial PLC $RTO

Dimensional Fund Advisors LP significantly reduced its stake in Rentokil Initial PLC by 45.9% in Q1 2026, selling over 138,000 shares but still retaining holdings valued at $5.1 million. Despite this reduction, other institutional investors increased their positions in Rentokil Initial. The company's stock …

Cytokinetics president & CEO Robert Blum sells $575,700 in shares

Robert I. Blum, President and CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of common stock for $575,700, while also acquiring 7,500 shares through option exercise for $79,500. Following these transactions, Blum directly holds 377,820 shares, with additional indirect holdings. This comes as CYTOKINETICS …

Tolu Minerals Shares Move Higher Today – Here’s Why

Is Stoke Therapeutics' (STOK) New Shelf Filing Reframing Its Path Through Mounting Operating Losses?

Stoke Therapeutics (STOK) reported a significant net loss of US$61.62 million in Q2 2026 and US$111.62 million for the first half of 2026, alongside a drop in sales. The company also filed a US$57.72 million shelf registration for 2,000,000 common shares, signaling potential future …

Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $575,700.00 in Stock

Cytokinetics CEO Robert Blum sold 7,500 shares of the company's stock for $575,700, reducing his direct holdings by 1.95%. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts generally maintain a "Moderate Buy" rating for CYTK with …

Cytokinetics, Incorporated Revenue Breakdown – NASDAQ:CYTK

Cytokinetics, Incorporated (NASDAQ: CYTK) generated $88.04 million USD in revenue last year, primarily from its Muscle Activators and Muscle Inhibitors segment. This represents a significant increase from the previous year's $18.47 million USD. The United States was the greatest contributor to this revenue.

CYTOKINETICS, INCORPORATED : LEERINK PARTNERS RAISES TARGET PRICE TO $103 FROM $100

LEERINK PARTNERS has increased its target price for CYTOKINETICS, INCORPORATED (CYTK.O) from $100 to $103. The article is a brief financial news update from Reuters, indicating a positive analyst sentiment towards the company. It notes that the content reflects only the author's opinion and …

Rentokil Initial PLC (RTO.L) Stock Analysis: Exploring a 33% Potential Upside Amidst Market Challenges

Rentokil Initial PLC (RTO.L), a global leader in pest control and hygiene services, shows a potential upside of 33.33% despite current market challenges. While the stock is trading below its moving averages and has a high forward P/E, analysts are optimistic with 12 buy …

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cytokinetics, Incorporated (NASDAQ:CYTK) on behalf of investors who purchased securities before December 27, 2023. The investigation seeks to determine if the company or its officers engaged in corporate wrongdoing. The law firm is encouraging …

It Might Not Be A Great Idea To Buy Rentokil Initial plc (LON:RTO) For Its Next Dividend

Cytokinetics (NASDAQ:CYTK) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS